Working… Menu

Ph I Dasatinib + Erlotinib in Recurrent MG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00609999
Recruitment Status : Completed
First Posted : February 7, 2008
Last Update Posted : July 16, 2014
Bristol-Myers Squibb
Genentech, Inc.
Information provided by (Responsible Party):
Duke University

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010